News

News

WEBINAR: Update on Biologic Drug IPRs: Lessons Learned

by Corinne E. Atton; Whitney L. Meier ; Robert S. Schwartz, Ph.D.
February 22, 2018

Lexology Webinar
February 22, 2018

 

Inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the USPTO have been popular since their inception in 2012, and petitions are increasingly being filed against biologic drug patents.  Venable Fitzpatrick’s award-winning intellectual property attorneys provide you with unique insights and the latest statistics on biologic drug IPRs and the lessons to be learned from recent institution and final written decisions.

Corinne Atton, Whitney Meier, and Robert Schwartz will discuss:

  • Statistics related to CDER-listed (“Purple Book”) biologic drug IPRs including: IPR petitions filed, patents challenged in both IPR and district court litigation, claim types challenged in IPR, IPR outcomes, and comparisons to data on IPRs filed against Orange Book listed patents.
  • Lessons learned from analyzing biologic drug IPRs by claim type: methods of treatment, formulation, composition of matter, and process/manufacturing.

This webinar is perfect for life sciences professionals interested in understanding how IPRs are being used to challenge biologic drug patents.

Click Here to View Webinar
Corinne Atton has experience litigating cases concerning a wide range of pharmaceuticals and biotechnology, including DNA sequences, DNA sequencing technologies, recombinant polypeptides, enzyme inhibitors, and antidiabetic drugs. She has a B.Sc. honors degree in Human Genetics.
Whitney Meier has experience litigating biochemistry, biotechnology, and pharmaceutical formulation patents. Whitney was awarded a B.S. degree in Biochemistry with high distinction.
Bob Schwartz has extensive experience litigating biotechnology and pharmaceutical patents, including those relating to antibodies, protein biochemistry, molecular biology, genomics and proteomics.  Bob has a B.S. in Biology and a Ph.D. in Biochemistry.  As a Principal Investigator of grant-funded research he published more than 40 articles in peer-reviewed publications and 7 book chapters.

    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha